Answers are grounded in this paper and cite their sources.
Adaptive Biomedical Innovation (ABI) is a multistakeholder approach to product and process innovation aimed at accelerating the delivery of clinical value to patients and society. ABI offers the opportunity to transcend the fragmentation and linearity of decision-making in our current model and create a common collaborative framework that optimizes the benefit and access of new medicines for patients as well as creating a more sustainable innovation ecosystem.
No takes yet. Share an insight, caveat, or question.
Honig et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: